GeoVax receives another $3.6M NIAID grant, Panacea shares freefall on delisted vax news;

Vaccine Research

A new study has shown the efficacy of the four 2009 H1N1 vaccines. According to researchers, H1N1 vaccinations could have cut flu-related doctor visits in half. Story

Vaccine Market

GeoVax Labs has received another $3.6 million funding influx from NIAID, part of its $19.6 million total grant backing for the company's AIDS vaccine research. The grant will be used to further a GM-CSF adjuvanted vaccine, one of many HIV vaccines the company is developing. Article

After the WHO delisted three of the company's vaccines, Panacea Biotec's shares skidded 20%. The delisted vaccines included a hepatitis B vaccine and a two-vaccine combo that protects against diptheria, pertussis and tetanus. News

Japan will loan Pakistan $65 million for 165 million oral polio vaccine doses in an effort to eradicate the disease. In the past, Japan has supported polio eradication with $87 million in oral polio vaccine funding via UNICEF. Item

Sinovac Biotech had a bump up in revenue in the second quarter, with $15.66 million compared to last year's $10.26 million. However, the company also posted a greater net loss, $1.79 million for the first 6 months of the year, while the first half of 2009's loss was $300,322. More

SL Pharmaceutical has earmarked CA$20 million towards a joint vaccine venture with PnuVax, called PnuVax SL Pharmaceutical. SL will have an 85% ownership of the group. Item

And Finally... Now entering the Republican presidential race, Texas Gov. Rick Perry has said mea culpa for backing mandatory HPV vaccinations during his tenure as governor. Report